Suzetrigine and Vepdegestrant interaction
Suzetrigine and Vepdegestrant: the Vepdegestrant prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Vepdegestrant (VEPPANU) label · effective 2026-06-12
Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers.
Strong CYP3A Inducers Prevention or Management Avoid concomitant use with strong CYP3A inducers in patients receiving VEPPANU 200 mg once daily.
Avoid concomitant use with strong CYP3A inducers in patients receiving VEPPANU 100 mg once daily.
Concomitant use with a strong CYP3A inducer may decrease vepdegestrant plasma concentration [see Clinical Pharmacology ( 12.3 )] , which may reduce the effectiveness of VEPPANU.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.